Prognostic value of microRNA-21 in intra- and extrahepatic cholangiocarcinoma after radical resection: cohort study
Lenka N.C. Boyd(Amsterdam University Medical Centers), Ingrid Garajová(University of Parma), Luca Morelli(University of Pisa), Laura L. Meijer(Erasmus MC), Tessa Y. S. Le Large(Amsterdam University Medical Centers), Hanneke W.M. van Laarhoven(Dutch Cancer Society), Mahsoem Ali(Amsterdam Neuroscience), Elisa Giovannetti(University of Pisa), Simona Tavolari(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Geert Kazemier(European Organisation for Research and Treatment of Cancer), Francesco Vasuri(Ospedale "Santa Maria delle Croci" di Ravenna), Giovanni Brandi(Hôpital Beaujon), Raffaele Gaeta(Azienda Ospedaliera Universitaria Pisana), Annalisa Comandatore(University of Pisa), Mattia Riefolo(Azienda USL di Bologna)
Cited by 1
Related Papers
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial
|The Lancet Oncology|2015|2.6k
Laparoscopic versus open pancreatoduodenectomy for pancreatic or periampullary tumours (LEOPARD-2): a multicentre, patient-blinded, randomised controlled phase 2/3 trial
|The Lancet. Gastroenterology & hepatology|2019|597
Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial
|The Lancet Oncology|2018|582
Analysis of Drug Interactions
|Methods in molecular biology|2011|252